Group 1 - The Hainan Free Trade Zone sector experienced significant gains, with notable stocks such as Caesar Travel (000796) hitting the daily limit up [1] - Kangzhi Pharmaceutical (300086) saw an increase of over 10%, indicating strong market interest [1] - Other companies that followed the upward trend include HNA Holding (600221), Jinpan Technology, Hainan Development (002163), Haide Shares (000567), and Shennong Seed Industry (300189) [1]

Core Viewpoint - The mosquito-repellent concept stocks continue to show strong performance, driven by the reported cases of Chikungunya fever in Foshan, with a total of 3,195 confirmed cases as of July 22, primarily concentrated in Shunde District [1] Group 1: Company Performance - Rainbow Group has achieved a consecutive two-day increase in stock price [1] - Kangzhi Pharmaceutical has seen a rise of over 10% in its stock price [1] - Other companies such as Runben Co., Wanfang Biological, Shanghai Jahwa, Qingsong Co., and Lafang Co. have also experienced stock price increases [1]

Group 1 - The outbreak of Chikungunya fever in Shunde District, Foshan, has reported a total of 2,934 confirmed cases as of July 22, 2025, with a significant increase of 463 cases in one day [1] - The World Health Organization (WHO) has indicated that 119 countries and regions have reported Chikungunya virus transmission, affecting approximately 5.5 million people at risk, potentially leading to widespread outbreaks [1][2] - The spread of Chikungunya fever is primarily through mosquito bites, with no direct human-to-human transmission, making it crucial to implement effective mosquito control measures to prevent further outbreaks [2] Group 2 - Companies in the relevant sectors are expected to gain market attention due to the ongoing outbreak [2] - Novogene's official WeChat account highlighted the challenges in detecting mosquito-borne viruses early due to low viral loads and complex samples, which affects testing efficiency [2] - Kangzhi Pharmaceutical has a subsidiary, Zhongshan Aihu, that offers a full range of baby and child care products, including disinfectants and mosquito repellent products [3]

Group 1 - The local stocks in Hainan showed strength on July 22, with companies like Zhongtung High-tech and Caesar Travel reaching their daily limit up, while Haide Co., Kangzhi Pharmaceutical, and Hainan Development also saw gains [1] - On July 21, the People's Bank of China and five other departments issued the implementation details for the cross-border asset management pilot in Hainan Free Trade Port, allowing foreign investors to invest in various financial products with an initial pilot scale cap of 10 billion [6] - The State Council Information Office will hold a press conference on July 23, 2025, to discuss the construction of Hainan Free Trade Port, featuring key officials from various ministries [6] Group 2 - The cross-border asset management business in Hainan Free Trade Port is expected to enrich the supply of cross-border financial products and attract asset management institutions to operate in Hainan, aiding the development of the free trade port [8] - Hainan aims to start full island closure operations by the end of 2025, positioning itself to align with international standards similar to Hong Kong, which may enhance its global trade competitiveness [7][8] - The independent nature of the offshore duty-free policy in Hainan is anticipated to remain, with expected benefits from consumption-boosting policies post-closure, including an increase in the variety and quantity of duty-free products [8]

Group 1: Product Overview - The company produces over 50 types of medicines, with more than 100 specifications, of which over 30 are pediatric drugs, covering the highest proportion of respiratory, digestive, anti-allergy, antibiotic, and nutritional supplements for children [1] - Pediatric drugs account for approximately 70% of the company's product mix, while adult drugs, including gynecological products, make up about 30% [1] Group 2: Market Potential - China's medical expenditure is expected to grow significantly, driven by increasing health awareness and a large base of approximately 250 million children aged 0-14, despite a declining birth rate [2] - The demand for pediatric medicines is stable, supported by parents' increasing focus on children's health, with certain segments like ADHD showing rising demand [2] Group 3: R&D Focus - The company has over 30 years of experience in pediatric drug R&D, continuously innovating in taste, dosage forms, and packaging to enhance competitiveness [2] - Future R&D will focus on pediatric medications, emphasizing dosage form innovation and expanding the pediatric population for existing drugs [4][5] Group 4: Sales Strategy - The company plans to enhance its sales channels, including increasing online sales and participating in national medical insurance negotiations [6] - The company is exploring acquisition opportunities primarily in the children's health sector, focusing on technology complementarity and channel synergy [7]

本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示：1、本次股东大会无增加、变更提案的情况。 2、本次股东大会以现场和网络投票相结合的方式召开。 证券代码：300086 证券简称：康芝药业 公告编号：2025-031 康芝药业股份有限公司 2024 年度股东大会决议公告 网络投票时间：2025 年 6 月 30 日。 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 6 月 30 日 上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票系统 投票的具体时间为：2025 年 6 月 30 日 9:15-15:00 期间的任意时间。 3、本次股东大会未出现否决议案的情形。 4、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、召开时间 现场会议召开时间：2025 年 6 月 30 日（星期一）下午 15:00 开始。 2、股权登记日：2025 年 6 月 25 日 3、现场会议召开地点：海口国家高新技术产业开发区药谷工业园药谷三路 6 号。 4、会议召集人：康芝药业股 ...

法 律 意 见 书 大成isDentons' PreferredLawFirminChina. 北京大成（海口）律师事务所 关于康芝药业股份有限公司2024年度股东大会的 北京大成（海口）律师事务所 北京大成（海口）律师事务所 关于康芝药业股份有限公司2024年度股东大会 的法律意见书 致：康芝药业股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范性文件的 要求，北京大成（海口）律师事务所（以下简称"本所"）接受康芝药业股份有限 公司（以下简称"公司"）的委托，指派律师参加公司2024年度股东大会（以下 简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集、召开程序、出席会议人员资格 、召集人资格、表决程序、表决结果发表法律意见，并不对本次股东大会所审议 的议案、议案所涉及的事项及内容发表意见。本所律师同意将本法律意见书随本 次股东大会其他信息披露资料一并公告。 本法律意见书仅供见证公司本次股东大会相关事项的合法性之目的使用，不 ...

证券代码：300086 证券简称：康芝药业 公告编号：2025-030 康芝药业股份有限公司 关于召开 2024 年度股东大会通知的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《中华人民共和国公司法》及《公司章程》的有关规定，经康芝药业股份有限公司 （以下简称"公司"）第六届董事会第十九次会议审议通过，公司决定于 2025 年 6 月 30 日 （星期一）在海口国家高新技术产业开发区药谷工业园药谷三路 6 号会议室召开 2024 年度股 东大会，本次会议将采取现场和网络投票相结合的表决方式。公司已于 2025 年 6 月 10 日在 巨潮资讯网（www.cninfo.com.cn）上披露了《关于召开 2024 年度股东大会的通知》（公告 编号：2025-028），为切实保护广大投资者的合法权益，方便公司股东行使表决权，现将本 次股东大会的有关事宜再次提示公告如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2024 年度股东大会。 2、股东大会的召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会召开经公司第六届董事会第十 ...

Group 1 - The company, Kangzhi Pharmaceutical Co., Ltd., will hold its 2024 Annual General Meeting on June 30, 2025, at its headquarters in Haikou [1][2] - The meeting will include both on-site and online voting options for shareholders [1][2] - Shareholders must register to attend the meeting, with specific procedures outlined for both corporate and individual shareholders [3][5] Group 2 - The voting will take place on June 30, 2025, with specific time slots for online voting through the Shenzhen Stock Exchange systems [2][4] - The agenda for the meeting includes proposals that have been approved by the company's board and supervisory committee [4][5] - Independent directors will present their reports during the meeting [4] Group 3 - Shareholders must hold shares as of the registration date, June 25, 2025, to be eligible to vote [3] - The company has provided detailed instructions for participating in online voting, including necessary identity verification steps [6][8] - Contact information for inquiries regarding the meeting is provided, including a specific contact person and phone number [6]

Core Viewpoint - The company plans to purchase liability insurance for its directors, supervisors, and senior management to enhance its risk management system and protect the interests of the company and its investors [1][2]. Group 1: Insurance Plan - The insurance contract will be negotiated based on market prices, with a premium not exceeding 300,000 yuan per year for renewal or reinsurance [2]. - The company aims to ensure that the insurance covers all directors, supervisors, and senior management, thereby promoting effective decision-making and management within their respective responsibilities [1][2]. Group 2: Authorization Matters - The board of directors has proposed to authorize the management to handle all matters related to the purchase of the liability insurance, including determining the scope of insured individuals, selecting the insurance company, and signing relevant legal documents [1][2]. Group 3: Review Procedure - The proposal for purchasing the liability insurance was reviewed by the board and supervisory committee, with all relevant parties abstaining from voting due to their status as insured individuals [2]. - The supervisory committee supports the purchase, stating it will improve the company's risk management and create a favorable governance environment for sustainable development [2].